US FDA panel backs restricted use of AstraZeneca’s prostrate cancer drug, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

The FDA panel voted 11-1 with one abstention, in favor of Lynparza, in combination with other medications , abiraterone and prednisone or prednisolone , as a first-line treatment for a type of treatment-resistant prostate cancer in adult patients. The panel also recommended against approval beyond this patient population., The FDA panel voted 11-1 with one abstention, in favor of Lynparza, in combination with other medications , abiraterone and prednisone or prednisolone , as a first-line treatment for a type of treatment-resistant prostate cancer in adult patients. The panel also recommended against approval beyond this patient population., , Read More